Alliancebernstein L.P. Kymera Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 124,614 shares of KYMR stock, worth $5.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124,614

Previous 93,668 33.04%

Holding current value

$5.23 Million

Previous $2.8 Million 110.98%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $933,331 - $1.62 Million	30,946 Added 33.04%	124,614 $5.9 Million
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $251,784 - $332,507	-8,435 Reduced 8.26%	93,668 $2.8 Million
Q1 2024 May 14, 2024	BUY	$22.9 - $43.57 $1.46 Million - $2.78 Million	63,703 Added 165.89%	102,103 $4.1 Million
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $4,388 - $10,736	400 Added 1.05%	38,400 $977,000
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $333,665 - $1 Million	-23,614 Reduced 38.33%	38,000 $748,000
Q1 2022 May 13, 2022	BUY	$35.3 - $64.68 $879,464 - $1.61 Million	24,914 Added 67.89%	61,614 $2.61 Million
Q3 2021 Nov 10, 2021	SELL	$47.8 - $66.66 $43,020 - $59,994	-900 Reduced 2.39%	36,700 $2.16 Million
Q2 2021 Jul 30, 2021	BUY	$31.08 - $51.95 $832,944 - $1.39 Million	26,800 Added 248.15%	37,600 $1.82 Million
Q1 2021 May 06, 2021	BUY	$35.64 - $85.46 $142,560 - $341,840	4,000 Added 58.82%	10,800 $420,000
Q4 2020 Feb 08, 2021	BUY	$28.07 - $87.83 $190,876 - $597,244	6,800 New	6,800 $422,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Kymera Therapeutics, Inc. Transaction History